Journal article

Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool

Kelly-Anne Phillips, Yuyan Liao, Roger L Milne, Robert J MacInnis, Ian M Collins, Richard Buchsbaum, Prue C Weideman, Adrian Bickerstaffe, Stephanie Nesci, Wendy K Chung, Melissa C Southey, Julia A Knight, Alice S Whittemore, Gillian S Dite, David Goldgar, Graham G Giles, Gord Glendon, Jack Cuzick, Antonis C Antoniou, Irene L Andrulis Show all

JNCI Cancer Spectrum | OXFORD UNIV PRESS | Published : 2019

Abstract

Background: iPrevent is an online breast cancer (BC) risk management decision support tool. It uses an internal switching algorithm, based on a woman's risk factor data, to estimate her absolute BC risk using either the International Breast Cancer Intervention Study (IBIS) version 7.02, or Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm version 3 models, and then provides tailored risk management information. This study assessed the accuracy of the 10-year risk estimates using prospective data. Methods: iPrevent-assigned 10-year invasive BC risk was calculated for 15 732 women aged 20-70 years and without BC at recruitment to the Prospective Family Study Coh..

View full abstract

Grants

Awarded by US National Institutes of Health (NIH), National Cancer Institute


Awarded by Australia National Health and Medical Research Council (NHMRC)


Awarded by Cancer Australia


Awarded by National Breast Cancer Foundation


Awarded by National Breast Cancer Foundation (Australia)


Awarded by Cancer Research UK


Awarded by National Cancer Institute


Funding Acknowledgements

This work was supported by the US National Institutes of Health (NIH), National Cancer Institute (1RO1CA159868); the Breast Cancer Research Foundation; Australia National Health and Medical Research Council (NHMRC) (454508, 288704, 145684); Victorian Health Promotion Foundation; Victorian Breast Cancer Research Consortium; Cancer Australia (809195); National Breast Cancer Foundation (IF 17); Queensland Cancer Fund; Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia; and Cancer Foundation of Western Australia. The six sites of the BCFR were supported by grant UM1 CA164920 from the National Cancer Institute.KAP is a National Breast Cancer Foundation (Australia) Practitioner Fellow (grant number PRAC-17-004). JLH is an NHMRC senior principal research fellow and a Redmond Barry Professorial Fellow. ACA is funded through Cancer Research UK (C12292/A20861, C12292/A22820). MCS is a NHMRC Senior Research Fellow (1061177).